GLP-1 Agonists Linked to Increased Risk of Eye Nerve Damage
Background
Recent observational studies have presented conflicting evidence regarding a potential association between glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), a class of drugs widely used for type 2 diabetes and obesity, and nonarteritic anterior ischemic optic neuropathy (NAION). NAION is a sudden, painless loss of vision due to insufficient blood supply to the optic nerve. Some reports suggested an increased incident risk of NAION and diabetic retinopathy with GLP-1RA use, particularly with longer durations of treatment. This study aimed to synthesize the pooled evidence from existing research to clarify the risk of NAION associated with GLP-1RA use.
Study Design
Results
The meta-analysis revealed a statistically significant increased risk of NAION among individuals using GLP-1RAs compared to non-users or those on other antidiabetic medications. The pooled analysis demonstrated a 1.42-fold increased risk of developing NAION (95% CI: 1.28-1.58, p<0.001). This risk appeared consistent across different GLP-1RA compounds, though semaglutide users showed a slightly higher, albeit not statistically distinct, 1.51-fold increased risk (95% CI: 1.30-1.75, p<0.001). The most important finding was a 42% higher likelihood of NAION diagnosis in patients treated with GLP-1RAs compared to control groups, indicating a notable ocular safety concern. Subgroup analysis suggested the risk was more pronounced in patients with pre-existing cardiovascular risk factors, with a 1.65-fold increase (p=0.003). The overall incidence rate of NAION in GLP-1RA users was estimated at 0.08% per year, compared to 0.05% in control groups.
Why It Matters
This meta-analysis provides compelling evidence of a potential association between GLP-1RA use and an increased risk of NAION, highlighting a crucial ocular safety consideration for millions of patients. Given the widespread and growing use of these medications for type 2 diabetes and obesity, these findings underscore the importance of patient counseling regarding potential visual side effects. Clinicians should be aware of this risk and consider it during patient assessment, especially for those with pre-existing risk factors for NAION. Further research, including prospective studies, is warranted to confirm causality and identify specific patient populations at highest risk, potentially leading to updated prescribing guidelines or enhanced monitoring protocols.